ANDA 200624, held by Lupin. Metformin Hydrochloride; Repaglinide.
As of Nov 15, 2026, ANDA 200624 (Repaglinide And Metformin Hydrochloride), held by Lupin, was first approved by FDA on Jul 15, 2015, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 15, 2015 | Original application | Approved |
| Repaglinide And Metformin Hydrochloride500MG;1MG · tablet;oral | Metformin Hydrochloride; Repaglinide | Discontinued |
| Repaglinide And Metformin Hydrochloride500MG;2MG · tablet;oral | Metformin Hydrochloride; Repaglinide | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
